stockrowIndivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
Follow SUPN
Alert me
Indivior Pharmaceuticals Inc. (SUPN) Revenue growth
Indivior Pharmaceuticals Inc.'s revenue growth over the twelve months to 30 September 2026 was 16.4%, up 12.1 percentage points from fiscal 2025 (4.29%). Over the past ten years it has ranged from −21.9% (fiscal 2019) to 22.3% (fiscal 2021); the current reading is higher than 55% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 5.22% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 4.29% | (4.40) |
| FY2024 | 8.69% | (12.62) |
| FY2023 | 21.3% | 7.40 |
| FY2022 | 13.9% | (8.35) |
| FY2021 | 22.3% | 39.84 |
| FY2020 | −17.6% | 4.31 |
| FY2019 | −21.9% | (13.84) |
| FY2018 | −8.05% | (11.36) |
| FY2017 | 3.31% | (1.03) |
| FY2016 | 4.34% | 13.40 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 13.4% | (0.20) |
| Jun 2026 | 13.6% | (5.59) |
| Mar 2026 | 19.2% | (0.63) |
| Dec 2025 | 19.8% | 17.52 |
| 41 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| LQDA Liquidia Corporation compare | 2,233.7% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 58.2% |
| HIMS Hims & Hers Health, Inc. compare | 28.0% |
| SUPN Indivior Pharmaceuticals Inc. | 16.4% |
| ALKS Alkermes plc compare | 15.3% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 8.88% |
| LNTH Lantheus Holdings, Inc. compare | 2.38% |
| RDY Dr. Reddy's Laboratories Ltd compare | −15.5% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −77.1% |
| Drug Manufacturers Specialty & Generic industry median | 5.22% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on SUPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement